The Royal Wolverhampton NHS Trust   Report issue

Academic/Hospital Phase 3 Phase 4
Founded: Wolverhampton United Kingdom (1994)

Organization Overview

First Clinical Trial
2015
NCT02376283
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

The Royal Wolverhampton Hospitals NHS Trust | The Royal Wolverhampton NHS Trust

Active Ingredients

Drugs in Phase 4 Trials (4)

cangrelor (kengreal) (1 trial)

clopidogrel (plavix) (1 trial)

prasugrel (effient) (1 trial)

ticagrelor (brilinta) (2 trials)

Drugs in Phase 3 Trials (1)

ferric maltol (Accrufer) (1 trial)

Drugs in Other Trials (2)

dobutamine (dobutrex) (1 trial)

licorice (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Angina, Unstable (Phase 4)

Infarction (Phase 4)

Myocardial Infarction (Phase 4)

ST Elevation Myocardial Infarction (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 7